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a  b  s  t  r  a  c  t
Background/objective: There is an increasing number of older patients with human immu-
nodeﬁciency virus infection due to the success of antiretroviral therapy, the improved
prognosis and life expectancy of patients, and the higher number of new infections among
older individuals. The main objective of the present study was to compare the characteristics
of  older human immunodeﬁciency virus patients with those of younger patients.
Materials and methods: We  conducted a cross-sectional study with human immunodeﬁ-
ciency virus-infected patients who were treated at the Specialized Care Service (Servic¸o de
Assistência Especializada) for human immunodeﬁciency virus/AIDS in the city of Pelotas,
South  Brazil. Sociodemographic information as well as data on human immunodeﬁciency
virus infection and treatment were collected. All participants underwent psychiatric and
neurocognitive assessments, and their adherence to antiretroviral therapy was evaluated.
Results: A total of 392 patients participated in the study, with 114 patients aged 50 years and
older. The characteristics showing signiﬁcant differences between older and younger human
immunodeﬁciency virus-infected patients included race/ethnicity, comorbidities, duration
and  adherence to antiretroviral therapy, currently undetectable viral load, and cognitiveimpairment. Compared to younger patients, older patients were at higher risk of exhibit-
ing  cognitive impairment [OR 2.28 (95% CI: 1.35–3.82, p = 0.002)] and of having increased
adherence to antiretroviral therapy [OR 3.11 (95% CI: 1.67–5.79, p < 0.001)].Conclusions: The prevalence of neurocognitive impairment remained high in human
immunodeﬁciency virus-infected patients despite antiretroviral therapy. In the present
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study, the prevalence of this type of impairment was signiﬁcantly higher in patients aged
≥50 years, most likely due to aging, human immunodeﬁciency virus infection, and a possi-
ble synergistic effect between these factors. Despite this higher prevalence, older patients
exhibited higher rates of adherence to antiretroviral therapy and of undetectable human
immunodeﬁciency virus viral load.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
s artian  open acces
Introduction
With the advent of antiretroviral therapy (ART), the prognosis
of human immunodeﬁciency virus (HIV)-infected individuals
has dramatically improved. The evolution of this therapy into
less complex regimens that are safer, easier to administer, and
have fewer side effects allows for viral replication to be con-
trolled indeﬁnitely in most patients.1,2 Despite the success of
ART, which led to the reduction of HIV-related opportunis-
tic diseases, HIV-infected individuals exhibit an increase in
non-AIDS-deﬁning illnesses that are typically related to aging,
such as cardiovascular diseases, dyslipidemia, diabetes mel-
litus, cancer, liver diseases, renal diseases, bone disorders,
and neurocognitive impairment (NCI).3,4 Aging is acceler-
ated in HIV-infected patients compared to non-HIV-infected
patients, with subjects aged 50 years and above being con-
sidered elderly.4–7 Several factors have been associated with
the above-mentioned differences in aging, including chronic
HIV infection, ART side effects, and accelerated aging of the
immune system.8–10
NCI in HIV-infected patients has remained highly preva-
lent even after the advent of ART. In addition to changes
associated with HIV (HIV-associated neurocognitive disorder
– HAND),11,12 other factors traditionally related to cognitive
impairment are present in HIV-infected patients and have a
signiﬁcant association with cognitive impairment in this pop-
ulation. The contribution of aging to the persistence of NCI
has driven growing interest in the study of patients using ART.
Several reports have shown a higher prevalence of cognitive
impairment among older HIV-infected patients compared to
younger patients using ART.13–16
There has been an increase in the population of older HIV-
infected adults due to increased number of new HIV infections
at more  advanced ages, the chronic nature of the infection,
and increases in life expectancy.17,18 Further studies are nec-
essary to better understand this population. The objectives of
this study were to (i) compare the characteristics of younger
HIV-infected patients with those of the older patients; (ii)
assess the prevalence of cognitive impairment in HIV-infected
patients after the advent of ART; (iii) determine whether an
association exists between cognitive impairment and aging
among other factors; and (iv) compare ART adherence in HIV-
infected patients aged ≤50 years with adherence of younger
patients.Materials  and  methods
This study was a cross-sectional study that recruited adult
HIV-infected individuals diagnosed according to the protocolcle under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
of the Brazilian Health Ministry. These patients were receiving
care at a Specialized Center (Servic¸o de Assistência Especial-
izada – SAE) for HIV/AIDS in the city of Pelotas, South Brazil,
in 2015. Patients with a previous neurological disease and/or
psychotic disorder were excluded from the study.
All patients treated at the SAE were invited to participate in
the study, and those who agreed signed the informed consent
form. The present study was approved by the Ethics Commit-
tee. Participants completed a sociodemographic questionnaire
and underwent psychiatric and neurocognitive assessments.
The instrument used for psychiatric assessment was the
International Neuropsychiatric Interview (MINI – Plus). The
neurocognitive assessment was performed using the follow-
ing instruments: Grooved Pegboard Test, Color Trails Test
(CTT) parts 1 and 2, Finger Tapping Test, Montreal Cognitive
Assessment, and the International HIV Dementia Scale (IHDS).
The cutoff point for the latter was a score of 10 or less. All of
the assessments were performed within the SAE premises.
Laboratory data and clinical features were abstracted from
the patients’ medical records. Collected information included
stage of HIV infection, use of ART, duration of treatment, time
of diagnosis, CD4 counts and viral load, and comorbidities.
HIV viral load was considered undetectable when less than
50 copies/mL.
Adherence to ART was measured by self-reporting and the
ﬁlling of prescriptions at the pharmacy over the previous three
months. The patients who reported to have not forgotten a
single dose of medication in the past three days and who  reg-
ularly ﬁlled the ART prescription at the SAE pharmacy over the
past three months were considered adherent.
Except for the IHDS, there are no standardized cutoff points
for the other neurocognitive assessment instruments in Brazil.
Therefore, the scores of the remaining instruments (MoCA,
CTT-1 and CTT-2, Finger Tapping Test, and Grooved Pegboard
Test) were distributed into quartiles. To obtain higher speci-
ﬁcity, the individuals who (i) scored in the upper quartile in at
least three of the ﬁve instruments used, and (ii) reached the
IHDS cutoff point were considered positive for NCI.
Evidence of cognitive impairment was also evaluated by the
Instrumental Activities of Daily Living (IADL) scale, as stan-
dardized by the Clinical Protocol and Therapeutic Guidelines
for the Management of HIV Infection in Adults of the Brazilian
Health Ministry.
Sociodemographic and clinical data were subjected to
descriptive analysis by calculating frequencies of categorical
variables, and the means and standard deviations of contin-
uous variables among patients aged 50 years or more  and
compared to those aged less than 50 years.
Multiple logistic regression was used to analyze the inde-
pendent association of age with NCI adjusted for prespeciﬁed






















Table 2 – Neurocognitive impairment and age.
<50 years ≥50 years ap
n = 278 n = 114
bIHDS (n, %) 139 (53.5) 73 (63.7) 0.008
bIHDS + cother tests (n, %) 81 (29.1) 61 (53.2) <0.001
IHDS (mean, SD) 9.44 (1.9) 8.51 (2.3) 0.006
Score IADL (n, %) 0.45
≤7 0 0
8/20 157 (56.6) 59 (52.3)
≥21 121 (43.3) 55 (47.5)
IHDS, International HIV Dementia Scale; IADL, instrumental activ-
ities of daily living.
a p-Values are calculated with X2 test or Fisher exact test.
c Other test = grooved pegboard, ﬁnger-tapping, color trials 1 and 2b r a z j i n f e c t d i s .
actors of interest (age, gender, race/ethnicity, education level
nd cumulative years on ART), in addition to factors with a
-value ≤0.2 in univariate analysis. The analyses were per-
ormed using SPSS software (version 21).
A possible independent association of age and adherence
o ART was also tested using multiple logistic regression.
esults
 total of 392 patients participated in the study, 114 of whom
ere aged 50 years or more  with a mean age of 56.7 years,
anging from 50 to 82 years.
Tables 1 and 2 show a comparison of the characteris-
ics of older and younger patients. The characteristics with
igniﬁcant differences included race/ethnicity, comorbidities
diabetes mellitus, hypertension and dyslipidemia), use of
RT, adherence to ART, duration of ART use, currently unde-
ectable viral load, and cognitive impairment (according to the
HDS and the combination of the IHDS and other instruments).
lder patients exhibited a higher prevalence of diabetes mel-
itus, hypertension and dyslipidemia. ART use was more
ommon among patients aged 50 years or more,  as was the
uration of ART and the rate of patients with undetectable
iral loads.
There was no difference in the prevalence of depression
mong the patient groups. The prevalence of NCI according
Table 1 – The characteristics of HIV-infected patients
aged <50 years and ≥50 years.
Characteristics <50 years ≥50 years pa
n = 278 n = 114
Age (mean, SD) 37.15  (7.9) 56.76 (7.1)
Gender (n, %)
Male 124 (44.6) 51 (44.5) 1.0
Race/ethnicity (n, %)
White 166 (59.7) 74 (64.9) 0.05
Non-white 112 (40.3) 40 (35.1)
Education level (n, %)
0–7 years 215 (77.4) 83 (72.9) 0.73
≥8 years 63 (22.6) 31 (27.1)
Comorbidities (n, %) 75 (27.0) 76 (66.7) <0.001
Use of ART (n, %)
First-line 164 (58.9) 63 (55) 0.01
More than one ART 78 (28.6) 45 (40)
Not using 36 (12.5) 6 (5)
Duration of ART (years) (mean, SD) 5.3 (4.2) 6.4 (4.9) 0.03
Current CD4 count ≤200 (n, %) 41 (13.3) 15 (13.2) 0.91
CD4 nadir ≤200 (n, %) 104 (37.4) 45 (39.4) 0.41
Time of diagnosis (years) (mean, SD) 7.7  (8.5) 7.2 (5.4) 0.61
Adherents (n, %) 149 (53.5) 80 (70.3) 0.03
Current VL < 50 (n, %) 160 (57.5) 94 (82.4) <0.001
Depression (n, %) 71 (25.7) 24 (21.3) 0.34
CD4 (cells/mm3), cluster of differentiation 4; VL (copies/mL), viral
load; ART, antiretroviral therapy; SD, standard deviation; pa values
are calculated with X2 test or Fisher exact test.and MoCa.
b IHDS = IHDS score ≤10.
to the IHDS and the combination of the IHDS and other
instruments was signiﬁcantly higher in older patients. The
education level was similar in both patient groups.
The association of an age ≥50 years with NCI remained
signiﬁcant after adjusting for gender, race/ethnicity, education
level, current CD4 count, nadir CD4 count, and duration of ART
[OR 2.28 (95% CI: 1.35–3.82, p = 0.002)]. In addition to age, other
factors shown to be associated with cognitive impairment in
the multivariate analysis were education level and nadir CD4
count (Table 3).
For patients using ART, adherence to treatment was signiﬁ-
cantly higher among older patients. This association remained
signiﬁcant after adjusting for gender, education level, nadir
CD4 count, duration of treatment, depression, and presence
of NCI [OR 3.11 (95% CI: 1.67–5.79, p < 0.001)].
Discussion
Despite the dramatic reduction in AIDS-related neurological
disorders that has occurred since the advent of ART, NCI is still
observed in HIV-infected patients and is a signiﬁcant prob-
lem in the management of these patients. Several factors
have been associated with cognitive impairment, including
advanced age, lower education level, cardiovascular risk fac-
tors, CD4 nadir count, the most recent CD4 count and viral
load.11,15,19–23
HIV frequently causes encephalopathy. Subcortical struc-
tures are mostly affected, leading to NCI, including deﬁcits
in attention, learning, memory,  information processing speed,
and problem solving skills.24 In 2007, the HAND criteria were
revised and classiﬁed into three conditions: asymptomatic
NCI, mild neurocognitive disorder, and HIV-associated demen-
tia (HAD). This nomenclature is referred to as the Frascati
criteria.25 Some studies have suggested that advanced age is
associated with a higher prevalence of HAD. Valcour et al.26
compared patients older than 50 years with younger patients,
ﬁnding that the risk of developing HAD was increased by 3.26
(1.32–8.07)-fold in older patients compared to younger patients
after adjusting for education level, race, drug addiction, the
use of ART, viral load, and CD4 count. In the present study,
the risk of exhibiting cognitive impairment was increased by
2.28 (1.35–3.82)-fold in older HIV-infected patients compared
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Table 3 – Multivariate analysis, cognitive impairment outcome.
Characteristics Crude model Adjusted model
OR (95% CI) p OR (95% CI) p
Gendera
Female 1 1
Male 1.15 (0.99–2.20) 0.06 0.75 (0.43–1.32) 0.32
Age (years)a
<50 1 1
≥50 2.04 (1.59–2.63) 0.001 2.28 (1.59–2.63) 0.002
Race/ethnicitya
White 1 1
Non-white 1.71 (1.04–2.83) 0.05 1.22 (0.98–2.03) 0.08
Education level (years)a
0–7 6.72 (3.98–11.32) <0.001 6.06 (3.98–11.32) <0.001
≥8 1 1
CD4 nadirb




>200 0.64 (0.39–1.37) 0.27 –
a
itial V
Adjusted for gender, age, race/ethnicity, education level.
b Adjusted for duration of HIV infection, CD4 nadir, current CD4, in
level.
to younger patients. The instruments used in the present
study primarily allowed for assessing impairment of cogni-
tive functions of the subcortical structures; however, it is not
possible to state that this cognitive impairment is secondary
to HIV activity on the central nervous system. For the diag-
nosis of HAND, the causes of cognitive impairment that are
traditionally related to cognitive deﬁcit and aging need to be
ruled out.
Older patients have a higher risk of exhibiting neurocog-
nitive disorders for causes that are traditionally associated
with aging. Cognitive functions become impaired with aging,
and advanced age is an important risk factor for most of the
neurodegenerative disorders that result in dementia. Recent
longitudinal studies have shown that the worst cognitive
deﬁcits and neurological impairment in older individuals liv-
ing with HIV result from (i) pathophysiological mechanisms
related to HIV infection of the nervous system, (ii) aging-
related factors,27–29 and (iii) a synergistic interaction between
HIV and aging.30,31 The study by Seider et al.30 reported
signiﬁcant decline in verbal memory  of older HIV-infected
patients. The cognitive performance of HIV-infected patients
aged 50 and 60 years was similar to that of HIV-negative
individuals aged 70 and 80 years, respectively. The present
study showed an increased prevalence of cognitive impair-
ment in HIV-infected patients, which is in agreement with the
literature.11,12 Furthermore, a higher prevalence of cognitive
impairment was found in HIV-infected patients aged 50 years
and above compared to younger HIV-infected adults, a result
that is in line with other published studies.13–16
The prevalence of cognitive impairment is higher in older
individuals in the general population, regardless of the HIVL, current VL, use of HAART, gender, age, race/ethnicity, education
status. The main causes of dementia are Alzheimer’s disease
and vascular dementia. According to international data, the
prevalence of Alzheimer ranges from 4.7 to 8.7% in individuals
over 60 years of age,32 and the prevalence of vascular dementia
ranges from 1.2 to 4.2% in individuals over 65 years of age.33,34
In addition to these causes of dementia, mild cognitive impair-
ment (MCI) in also present in older individuals, affecting
primarily individuals older than 65 years. The prevalence of
MCI ranges from 3 to 22%,35,36 depending on the population
studied and the criteria used for its deﬁnition. Brazilian stud-
ies estimate that the prevalence of cognitive and functional
impairment in older individuals is between 16 and 19.9%.37–39
In our study, the prevalence of cognitive impairment in HIV-
infected patients aged ≥50 years was 53.2%, which is higher
than that reported in the literature, especially considering that
the mean age of our sample was 57 years and the age consid-
ered in studies in non-infected populations is >60 years of age.
The extent to which cognitive impairment is (i) secondary to
HIV, (ii) secondary to other diseases (e.g., Alzheimer’s disease
and vascular dementia) or (iii) the result of a synergetic action
of HIV with age-related factors that lead to cognitive impair-
ment is not well understood. Comorbidities, such as diabetes,
hypertension, and dyslipidemia, were more  prevalent in older
patients of the present study, as expected. The contribution of
chronic HIV infection and the use of ART to these increased
prevalence in HIV-infected patients could not be assessed in
this study.Despite the higher prevalence of NCI, adherence to ART
was higher in older patients than in younger patients in the
present study. Older patients used ART longer and had a
higher rate of undetectable viral loads, which is consistent





































































disorders and depression in a Brazilian HIV population. Revb r a z j i n f e c t d i s .
ith better adherence. The above-mentioned higher preva-
ence of adherence among older HIV-infected patients is in
greement with several studies, suggesting that patients of the
ge-range tended to adhere more  promptly to treatment than
ounger patients.40–43 A recent meta-analysis43 showing that
lder HIV-infected patients had a lower risk of non-adherence
einforces this ﬁnding. Older patients generally have a higher
revalence of factors associated with non-adherence; how-
ver, paradoxically, older patients with HIV are more  likely to
dhere to treatment. Perhaps these patients have been able
o maintain ART for a longer period of time due to different
actors, such as higher tolerability, and thus are less likely
o experience complications that result from severe immu-
odeﬁciency and that are responsible for higher short-term
ortality.
Among psychiatric disorders, depression is frequently
iagnosed in HIV/AIDS patients, with a prevalence ranging
etween 12% and 66%.19,44–49 In Brazil, studies estimate a
revalence between 32% and 34%.19,46 The study by Passos
t al. in the city of Pelotas, Rio Grande do Sul State, Brazil,
evealed a high risk of suicide (34.1%).47 Notably, our study
ound an increased prevalence of depression both in older
nd younger patients, with no signiﬁcant difference between
he groups. Published studies comparing the prevalence of
epression among older and younger HIV-infected patients
ave reported discordant results.48,49
The present study has some limitations. First, the sam-
le of patients aged 50 years and older was small, reducing
he power to detect possible associations of cognitive impair-
ent with factors present among older patients. Second, the
nstruments for measuring cognitive impairment are not yet
ully validated in Brazil, with the exception of the IHDS.50 Nev-
rtheless, the prevalence found in our study was similar to
he prevalence reported in other studies.19,21 Another limita-
ion is the evaluation of adherence to ART. Speciﬁcally, the
se of self-reporting and the short evaluation period (three
onths) of the ﬁlling of ART prescriptions at the pharmacy
ay have resulted in an overestimation of adherence. How-
ver, there was a signiﬁcant association between adherence
nd an undetectable viral load, reinforcing the validity of the
ethodology.
The population of HIV-infected individuals is aging. There-
ore, studies aiming at understanding the behavior of HIV
nfection in this population are necessary. Most of the results
hat have been published to date have been conducted in
igh income countries, where the characteristics of the older
atient population differ from those of the Brazilian pop-
lation. The goal of the present study was to describe the
haracteristics of the patient population aged 50 years and
lder in a sample from South Brazil. Our results were sim-
lar to those from other international studies with respect
o cognitive impairment and adherence to treatment.14,15,43
rospective studies with a larger sample of HIV-infected indi-
iduals at advanced age in Brazil are necessary to better
nderstand the characteristics of this population, and the
esults will allow for improved management of these patients.
urthermore, the easy-to-apply instruments for the diagnosis
f HAND need to be validated in Brazil in order to provide a
ore  uniform diagnosis and evaluation of factors related to
CI in our country.
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